Skip to main content
. 2019 Nov 19;19(1):460–468. doi: 10.3892/ol.2019.11111

Figure 2.

Figure 2.

c-myc is transcriptionally upregulated in WERI-Rb1 cells following treatment with the histone deacetylase inhibitor TSA. (A) RT-PCR analysis indicated that c-myc was upregulated by TSA in a dose-dependent manner in WERI-Rb1 cells. (B) Western blot analysis of c-Myc in WERI-Rb1 cells following TSA treatment. GAPDH is shown as an internal control. (C) Relative expression of the c-Myc protein in WERI-Rb1 following TSA treatment at different time points. Data are presented as histograms. (D) Expression of c-Myc (red) was visualized in WERI-Rb1 cells after TSA treatment, and compared with the control. Magnification, ×100. (E) Luciferase plasmid structure, which contains a c-myc promoter sequence from −2,263 to +53 bp. (F) WERI-Rb1 cells were transfected with the reporter containing the c-myc promoter and subsequently treated with 250 nM TSA for 24 h. Levels of luciferase activity were normalized to those of Renilla luciferase (control, 1; TSA, 1.53±0.18; n=3 for each group). All results were confirmed in triplicate. *P<0.05 vs. respective control. RT-PCR, reverse transcription PCR; BP, base pairs; TSA, trichostatin A; con, control.